Tarlatamab

Therapeutic indications

Tarlatamab is indicated for:

Extensive-stage small cell lung cancer (ES-SCLC) - monotherapy

Population group: only adults (18 years old or older)

Tarlatamab is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tarlatamab is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈